Evidence map›Paper›PMID 27601574›Full record

ArticlemBio2016

aroA-Deficient Salmonella enterica Serovar Typhimurium Is More Than a Metabolically Attenuated Mutant.

Sebastian Felgner, Michael Frahm, Dino Kocijancic, Manfred Rohde, Denitsa Eckweiler, Agata Bielecka, Emilio Bueno, Felipe Cava, Wolf-Rainer Abraham, Roy Curtiss and 3 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. The renaissance ofFrontiers in immunology · 2026
    Review
  5. AttenuatedFrontiers in immunology · 2026
    Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. TheVaccines · 2024
    Article
  13. Article
  14. Attenuated mutants ofExperimental biology and medicine (Maywood, N.J.) · 2024
    Article
  15. Article
  16. Article
  17. Current advances in microbial-based cancer therapies.Medical oncology (Northwood, London, England) · 2023
    Review
  18. Frontiers in cellular and infection microbiology · 2023
    Review
  19. Recombinant AttenuatedCancers · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Sebastian FelgnerDepartment of Molecular Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany sebastian.felgner@helmholtz-hzi.de.
Michael FrahmDepartment of Molecular Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Dino KocijancicDepartment of Molecular Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Manfred RohdeCentral Facility for Microscopy, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Denitsa EckweilerDepartment of Molecular Bacteriology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Agata BieleckaDepartment of Molecular Bacteriology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Emilio BuenoDepartment of Molecular Biology, Umeå University, Umeå, Sweden.
Felipe CavaDepartment of Molecular Biology, Umeå University, Umeå, Sweden.
Wolf-Rainer AbrahamDepartment of Chemical Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Roy CurtissDepartment of Infectious Diseases and Pathology, University of Florida, Gainesville, Florida, USA.
Susanne HäusslerDepartment of Molecular Bacteriology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Marc ErhardtJunior Research Group Infection Biology of Salmonella, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Siegfried WeissDepartment of Molecular Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany Institute of Immunology, Medical School Hannover, Hannover, Germany.
Helmholtz Centre for Infection Research · DEUmeå University · SEMedizinische Hochschule Hannover · DEUniversity of Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledRecombinant attenuated Salmonella enterica serovar Typhimurium strains are believed to act as powerful live vaccine carriers that are able to elicit protection against various pathogens. Auxotrophic mutations, such as a deletion of aroA, are commonly introduced into such bacteria for attenuation without incapacitating immunostimulation. In this study, we describe the surprising finding that deletion of aroA dramatically increased the virulence of attenuated Salmonella in mouse models. Mutant bacteria lacking aroA elicited increased levels of the proinflammatory cytokine tumor necrosis factor alpha (TNF-α) after systemic application. A detailed genetic and phenotypic characterization in combination with transcriptomic and metabolic profiling demonstrated that ΔaroA mutants display pleiotropic alterations in cellular physiology and lipid and amino acid metabolism, as well as increased sensitivity to penicillin, complement, and phagocytic uptake. In concert with other immunomodulating mutations, deletion of aroA affected flagellin phase variation and gene expression of the virulence-associated genes arnT and ansB Finally, ΔaroA strains displayed significantly improved tumor therapeutic activity. These results highlight the importance of a functional shikimate pathway to control homeostatic bacterial physiology. They further highlight the great potential of ΔaroA-attenuated Salmonella for the development of vaccines and cancer therapies with important implications for host-pathogen interactions and translational medicine. IMPORTANCE: Recombinant attenuated bacterial vector systems based on genetically engineered Salmonella have been developed as highly potent vaccines. Due to the pathogenic properties of Salmonella, efficient attenuation is required for clinical applications. Since the hallmark study by Hoiseth and Stocker in 1981 (S. K. Hoiseth and B. A. D. Stocker, Nature 291:238-239, 1981, http://dx.doi.org/10.1038/291238a0), the auxotrophic ΔaroA mutation has been generally considered safe and universally used to attenuate bacterial strains. Here, we are presenting the remarkable finding that a deletion of aroA leads to pronounced alterations of gene expression, metabolism, and cellular physiology, which resulted in increased immunogenicity, virulence, and adjuvant potential of Salmonella. These results suggest that the enhanced immunogenicity of aroA-deficient Salmonella strains might be advantageous for optimizing bacterial vaccine carriers and immunotherapy. Accordingly, we demonstrate a superior performance of ΔaroA Salmonella in bacterium-mediated tumor therapy. In addition, the present study highlights the importance of a functional shikimate pathway to sustain bacterial physiology and metabolism.

Indexed as

Gene Deletion3-Phosphoshikimate 1-CarboxyvinyltransferaseAnimalsBacterial ProteinsBody WeightDisease Models, AnimalGene Expression ProfilingHost-Pathogen InteractionsMetabolic Networks and PathwaysMetabolomicsMiceSalmonella InfectionsSalmonella typhimuriumShikimic AcidTumor Necrosis Factor-alphaVirulence3-Phosphoshikimate 1-CarboxyvinyltransferaseBacterial ProteinsShikimic AcidTumor Necrosis Factor-alphaVirulence Factors

Identifiers

PMID27601574
PMCPMC5013297
OpenAlexW2509070479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.